Revenue Growth - Acquisition revenues for Q3 2025 increased 217.6% to $14.8 million compared to $4.7 million in Q3 2024, primarily due to increased crew utilization [94] - Canadian acquisition revenues for Q3 2025 rose to $166,000 from $11,000 in Q3 2024, with a 53.9% increase to $13.0 million for the first nine months of 2025 compared to $8.5 million in the same period of 2024 [95] - Total revenues for Q3 2025 were $22.7 million, up from $14.4 million in Q3 2024, despite a $2.0 million decrease in reimbursable revenues [96] Operating Costs and Expenses - Total operating costs for Q3 2025 were $23.9 million, an 18.6% increase from Q3 2024, while operating expenses for the first nine months of 2025 decreased 17.8% to $51.2 million [102] - General and administrative expenses decreased 19.8% to $2.1 million in Q3 2025 compared to $2.6 million in Q3 2024, reflecting cost reduction initiatives [100] Equipment and Capital Expenditures - The company entered into an equipment purchase agreement for new single point node channels for approximately $24.2 million, with $4.8 million paid upon execution and $18.2 million financed through promissory notes [90] - As of September 30, 2025, the company had taken delivery of $10.4 million of equipment and issued two promissory notes totaling approximately $7.5 million [91] - Capital expenditures for the nine months ended September 30, 2025, totaled $12.6 million, primarily for new node channels and maintenance capital requirements [113] Cash Flow and Financing Activities - For the nine months ended September 30, 2025, net cash provided by operating activities was $11.9 million, an increase from $3.6 million for the same period in 2024, primarily due to an increase in deferred revenue [110] - Net cash used in investing activities increased to $5.7 million for the nine months ended September 30, 2025, compared to $0.9 million for the same period in 2024, driven by a rise in capital expenditures to $6.1 million from $1.6 million [111] - Net cash used in financing activities was $2.5 million for the nine months ended September 30, 2025, down from $11.4 million in the same period of 2024, which included $9.9 million in dividends paid [112] Debt and Interest Expenses - Interest expenses for Q3 2025 were $71,000, up from $35,000 in Q3 2024, primarily due to additional debt from capital leases and new equipment notes [103] - The company executed Geospace Notes totaling approximately $7.5 million, with a fixed interest rate of 8.75% and monthly payments of about $239,000 [121] - The company has finance leases totaling $2.5 million as of September 30, 2025, with interest rates ranging from 4.86% to 8.74% [123] Tax and Market Risk - The effective tax rate for Q3 2025 was -0.9%, compared to 0.6% for Q3 2024, influenced by net operating loss carryovers and adjustments to deferred tax assets [104] - No material change in market risk profile during the three months ended September 30, 2025 [131] - Company is exposed to credit risk and interest rate changes due to financial instruments used in business operations [132] - No hedge arrangements or derivative financial instruments have been entered into by the company [132] - Business operations in Canada expose the company to foreign currency exchange rate risk [132] Future Outlook - The company expects to ramp up seasonal operations in Canada and has multiple small channel crew jobs contracted for Q4 2025, anticipating revenue growth quarter-over-quarter [92] - The company believes its capital resources will be adequate to meet current operational needs and fund future capital requirements, depending on future operating performance [126] - The maximum borrowing limit under the Revolving Credit Note is $5,035,032, with a 13% interest rate, payable in 36 monthly installments [117] Dividends - The company declared a special cash dividend of $0.32 per share, totaling approximately $9.9 million, paid on May 6, 2024 [115]

IPO Details - The company completed its Initial Public Offering (IPO) on September 22, 2025, raising gross proceeds of $172.5 million from the sale of 17,250,000 Units at $10.00 per Unit[115]. - The company incurred total costs of $10,060,403 related to the IPO, including $3,450,000 in cash underwriting fees and a Deferred Fee of up to $6,037,500[122]. - The company has until September 22, 2027, to complete its Business Combination, or it will cease operations and redeem Public Shares at a cash price equal to the amount in the Trust Account[118]. Financial Performance - The company generated a net income of $43,587 for the three months ended September 30, 2025, primarily from interest income of $151,164 on marketable securities held in the Trust Account[121]. - As of September 30, 2025, the company had approximately $172,651,164 in marketable securities in the Trust Account, including $151,164 of interest income[124]. - The company has not generated any operating revenues to date and will not do so until after the completion of its initial Business Combination[120]. Cash and Funding - The company has cash held outside the Trust Account amounting to $1,098,128, intended for evaluating target businesses and related activities[126]. - The company has not yet borrowed under any Working Capital Loans as of September 30, 2025[129]. - The company has incurred $4,000 in fees for administrative services for the three months ended September 30, 2025[131]. Accounting Policies and Estimates - The company has identified critical accounting policies that may affect reported amounts of assets and liabilities, income and expenses[136]. - As of September 30, 2025, there were no critical accounting estimates disclosed that could materially affect the financial statements[137]. - Class A Ordinary Shares subject to possible redemption are classified as temporary equity and presented at redemption value outside of shareholders' equity[138]. - Net income per Ordinary Share is calculated using the two-class method, allocating net income pro rata to different classes of shares[139]. - Management does not anticipate any recently issued accounting standards to have a material effect on the financial statements[141]. Regulatory and Compliance - The FASB issued ASU 2023-07, effective for fiscal years beginning after December 15, 2023, requiring disclosures of significant segment expenses and performance measures[140]. - The company adopted ASU 2023-07 on September 22, 2025, coinciding with the Initial Public Offering[140]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[142]. Business Combination and Shareholder Approval - The company may seek to extend the Combination Period with shareholder approval, which could affect its ability to maintain its Nasdaq listing[119].

Financial Performance - ORIC Pharmaceuticals reported a net loss of $99.0 million for the nine months ended September 30, 2025, with an accumulated deficit of $661.7 million[77]. - Other income, net for the nine months ended September 30, 2025, was $9.5 million, a decrease of $2.3 million from $11.8 million in the same period of 2024[89]. - ORIC Pharmaceuticals anticipates significant losses will continue as it advances its clinical programs, particularly ORIC-944 and enozertinib[77]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2025, were $28.8 million, a decrease of $2.4 million compared to $31.2 million in the same period of 2024[89]. - For the nine months ended September 30, 2025, research and development expenses increased to $84.0 million, up 2.3% from $82.1 million in the same period of 2024[91]. - Research and development expenses for Q3 2025 were $28.8 million, a decrease of 7.7% from $31.2 million in Q3 2024[90]. General and Administrative Expenses - General and administrative expenses increased to $7.9 million for the three months ended September 30, 2025, compared to $7.1 million in the same period of 2024[89]. - For the nine months ended September 30, 2025, general and administrative expenses rose to $24.5 million, a 15.6% increase from $21.2 million in the same period of 2024[94]. - General and administrative expenses for Q3 2025 were $7.9 million, an increase of 11.3% from $7.1 million in Q3 2024[93]. Operating Expenses - Total operating expenses for the nine months ended September 30, 2025, were $108.5 million, an increase of $5.1 million from $103.3 million in the same period of 2024[89]. Cash Flow and Financial Resources - Net cash used in operating activities for the nine months ended September 30, 2025, was $88.5 million, compared to $84.6 million in the same period of 2024[104]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $243.8 million, significantly higher than $126.0 million in the same period of 2024[110]. - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $413.0 million[116]. - The company expects its current financial resources to support operations into the second half of 2028[99]. - The company raised approximately $125.0 million from a private placement of common stock in May 2025[95]. - The company anticipates substantial additional capital will be required to develop product candidates and fund operations in the future[98]. Clinical Trials and Pipeline - ORIC-944 demonstrated a PSA50 response rate of 55% and a PSA90 response rate of 20% in patients with metastatic castration-resistant prostate cancer[74]. - Enozertinib is in a Phase 1b trial for advanced solid tumors, with initial data showing systemic and intracranial activity[75]. - A strategic pipeline prioritization was announced on August 12, 2025, resulting in a 20% workforce reduction and a one-time cost of approximately $1.9 million[85]. - The company expects to report dose optimization data for ORIC-944 in the first quarter of 2026 and initiate a Phase 3 trial in the first half of 2026[74].

Financial Performance - Aardvark Therapeutics reported a net loss of $16.3 million for Q3 2025, compared to a net loss of $4.2 million in Q3 2024, reflecting a significant increase in operating expenses[5]. - Total operating expenses for Q3 2025 were $17.7 million, compared to $5.1 million in Q3 2024, indicating a substantial increase in operational costs[9]. Research and Development - Research and development expenses rose to $13.7 million in Q3 2025 from $4.1 million in Q3 2024, primarily due to increased development costs related to ARD-101[5]. - Aardvark plans to advance ARD-201 into two Phase 2 trials, POWER and STRENGTH, to evaluate its effectiveness in weight management and glucose control[2]. - Preclinical data indicated that ARD-201 achieved approximately 19% weight reduction after 30 days and around 30% weight loss when combined with low-dose tirzepatide[5]. - The Phase 3 HERO trial for ARD-101 has expanded eligibility to pediatric patients aged 10 and above, increasing the potential target market for Prader-Willi Syndrome treatment[3]. - Topline data from the Phase 3 HERO trial is expected in Q3 2026, while preliminary data from the Phase 2 POWER trial is anticipated in the second half of 2026[5]. Financial Position - As of September 30, 2025, Aardvark had cash, cash equivalents, and short-term investments totaling $126.4 million, sufficient to fund operations into 2027[5]. - Aardvark's total assets as of September 30, 2025, were $133.2 million, up from $77.5 million at the end of 2024, reflecting growth in current assets[11]. General and Administrative Expenses - General and administrative expenses increased to $4.0 million in Q3 2025 from $1.0 million in Q3 2024, attributed to higher personnel-related costs and professional fees[5].

Financial Performance - GAAP revenue for Q3 2025 was $11.5 million, a decrease from $12.6 million in Q3 2024[6] - Revenue for Q3 2025 was $11,514 million, a decrease of 8.3% compared to $12,553 million in Q3 2024[31] - For the nine months ended September 30, 2025, Archenia's estimated revenue was over $14 million, with a projected full-year revenue of more than $17 million[16] - Marchex anticipates a revenue growth run rate of approximately 10% in 2026, driven by ongoing product launches and platform migration completion[4] - Marchex believes the combined company could achieve quarterly revenue run rates of approximately $15 million, or $60 million annualized, with growth in the 15-20% range in 2026[24] Adjusted EBITDA - Adjusted EBITDA for Q3 2025 was $0.6 million, up from $0.3 million in Q3 2024, with a potential adjusted EBITDA gain of $1.1 million after excluding reorganization costs[6] - Adjusted EBITDA for Q3 2025 was $621 million, an increase of 98.7% from $313 million in Q3 2024[35] - The company expects Adjusted EBITDA margins to reach 10% or more in 2026 due to increasing revenue and lower operating expenses[4] - Marchex expects sequentially lower revenue and Adjusted EBITDA in Q4 2025 due to typical seasonality and revenue migration dilution[5] Operating Expenses and Losses - Total operating expenses for Q3 2025 were $12,455 million, down from $13,378 million in Q3 2024, reflecting a reduction of 6.9%[31] - Net loss applicable to common stockholders for Q3 2025 was $1,020 million, compared to a loss of $831 million in Q3 2024, representing a 22.7% increase in losses[31] - Basic and diluted net loss per share for Q3 2025 remained at $(0.02), consistent with Q3 2024[37] - Stock-based compensation for Q3 2025 was $920 million, significantly higher than $411 million in Q3 2024[35] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $10,321 million, down from $12,767 million at the end of 2024[33] - Total assets decreased to $41,145 million as of September 30, 2025, from $43,200 million at the end of 2024[33] - Total liabilities decreased to $9,203 million as of September 30, 2025, from $10,567 million at the end of 2024[33] - The company reported a total accumulated deficit of $(329,096) million as of September 30, 2025, compared to $(326,178) million at the end of 2024[33] Strategic Initiatives - Marchex has entered into an agreement to acquire Archenia for a $10 million convertible promissory note, with interest at 6%[12] - The potential combination with Archenia could create a vertically focused, AI-driven customer acquisition platform, enhancing revenue scale and market reach[17] - The company launched new AI-powered solutions for healthcare and senior living industries, enhancing its product offerings[10][11]

Financial Performance - Total revenues for the three months ended September 30, 2025, were $2,922,000, a significant increase from $953,000 in the same period of 2024, representing a growth of 206%[23] - The company reported a net loss of $146,344,000 for the three months ended September 30, 2025, compared to a net loss of $23,978,000 for the same period in 2024, indicating a substantial increase in losses[23] - For the nine months ended September 30, 2025, the company reported a net loss of $227,139,000, compared to a net loss of $106,508,000 for the same period in 2024, representing an increase in loss of approximately 113%[38] - The company experienced a net loss of $23,978,000 for the quarter ending September 30, 2024, compared to a net loss of $106,508,000 for the previous quarter, indicating a significant reduction in losses[33] - Net loss attributable to common shareholders reached $325.3 million, compared to $24.0 million in the same period last year, reflecting an increase of less than 200%[191] - Net loss per share attributable to common shareholders increased to $1.06 from $0.09, primarily due to changes in fair value of warrant liabilities and a deemed dividend[198] Revenue Sources - The company reported collaboration and licensing revenue of $1,818,000 for the three months ended September 30, 2025, compared to no revenue in the same period of 2024[23] - Total revenues increased by $2.0 million, or over 200%, primarily driven by collaboration and licensing revenues, with $1.8 million recognized from a terminated agreement[192] - Product revenues rose to $162,000, a 145.5% increase from $66,000 in the prior year[191] - Service revenues increased by 6.3%, reaching $942,000 compared to $886,000 in the previous year[191] Expenses and Costs - Research and development expenses for the nine months ended September 30, 2025, were $34,343,000, down from $41,312,000 in the same period of 2024, reflecting a decrease of 17%[23] - Selling, general and administrative expenses surged by $14.2 million, or 144%, driven by costs associated with Papzimeos commercial readiness[195] - Operating loss for the three months ended September 30, 2025, was $34.5 million, a 62.2% increase from $21.3 million in the prior year[191] - The company reported stock-based compensation of $2,061,000 for the quarter ending September 30, 2024, reflecting ongoing investment in employee incentives[30] - The company recognized a significant increase in stock-based compensation expense, which rose to $8,703,000 in 2025 from $6,606,000 in 2024, reflecting a 32% increase[38] Assets and Liabilities - Cash and cash equivalents decreased to $14,322,000 as of September 30, 2025, from $29,517,000 as of December 31, 2024, a decline of 51%[17] - Total assets increased to $171,264,000 as of September 30, 2025, compared to $145,266,000 as of December 31, 2024, representing a growth of 18%[19] - The company’s total liabilities rose to $129,396,000 as of September 30, 2025, up from $78,535,000 as of December 31, 2024, an increase of 65%[20] - The accumulated deficit increased to $(2,317,845,000) as of September 30, 2025, compared to $(2,090,706,000) as of December 31, 2024, indicating a worsening financial position[20] Stock and Equity - The weighted average shares outstanding for the three months ended September 30, 2025, were 307,170,490, compared to 275,881,170 for the same period in 2024, reflecting an increase in shares[23] - The total common stock shares outstanding increased to 292,869,097 as of September 30, 2024, up from 252,656,151 shares at June 30, 2024, representing a growth of approximately 15.9%[30] - Precigen, Inc. issued 39,878,939 shares in public offerings, net of issuance costs, contributing to the increase in total equity[33] - The company converted all holders of preferred stock to common stock in the third quarter of 2025, impacting the equity structure[75] Financing Activities - The company’s net cash provided by financing activities was $90,562,000 for the nine months ended September 30, 2025, compared to $32,179,000 for the same period in 2024, showing a substantial increase in financing[41] - The company entered into a Loan Agreement on September 3, 2025, securing a senior secured term loan facility of up to $125 million, with net proceeds of $92,818 after expenses[108] - The effective interest rate for the Term Loan was 12.5% for the three months ended September 30, 2025, with total interest expense of $902[112] Regulatory and Clinical Developments - The company received FDA approval for Papzimeos™ (Zopapogene Imadenovec) in August 2025, marking its transition from a development-stage to a commercial-stage company[44] - The FDA granted full approval of Papzimeos in August 2025, marking it as the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP)[167] - Papzimeos demonstrated a 51% complete response rate in a pivotal clinical trial, with 18 out of 35 patients requiring no surgeries in the 12 months post-treatment[169] - The FDA granted priority review for the company's BLA for PRGN-2012, with a target action date set for August 27, 2025[152] Strategic Initiatives - The company has initiated a strategic prioritization of its clinical portfolio, including a workforce reduction of over 20% to focus on the commercialization of Papzimeos[48] - The company is focusing on strategic partnerships to advance its UltraCAR-T programs, including PRGN-3006 in AML[173] - The proprietary UltraPorator device is designed to streamline and ensure rapid manufacturing of UltraCAR-T therapies, representing a significant advancement in the field[172] Other Financial Metrics - The company recorded a cumulative catch-up adjustment of $2,266 for stock-based compensation upon FDA approval of the BLA[140] - The total lease liabilities as of September 30, 2025, amounted to $5,302,000, with a current portion of $1,123,000[145] - The company had no outstanding balance on its $5 million revolving line of credit as of September 30, 2025, which bore interest at 8.00% per annum[114]

Financial Performance - Phio Pharmaceuticals reported a net loss of $2.4 million for Q3 2025, compared to a net loss of $1.5 million in Q3 2024, reflecting an increase in operating expenses[12]. - Total operating expenses for Q3 2025 were $2.5 million, compared to $1.6 million in Q3 2024[20]. Research and Development - Research and development expenses increased to $1.2 million in Q3 2025 from $0.6 million in Q3 2024, primarily due to higher clinical trial costs[10]. - In the ongoing Phase 1b trial of PH-762, 100% tumor clearance was achieved in one patient, with over 90% clearance in another and over 50% in a third patient[2]. - A total of 18 patients have completed treatment in the Phase 1b trial, with 6 achieving complete response and 2 achieving near complete response[3]. - The company has no reported dose-limiting toxicities or clinically relevant adverse effects in patients receiving PH-762[4]. Cash and Assets - As of September 30, 2025, the company had cash and cash equivalents of approximately $10.7 million, up from $5.4 million at December 31, 2024[9]. - The company’s total assets increased to $11.5 million as of September 30, 2025, compared to $5.7 million at December 31, 2024[22]. Future Financing - The company expects to raise approximately $12.1 million from warrant inducement financing, extending its cash runway into the first half of 2027[8]. Operating Expenses - General and administrative expenses rose to $1.3 million in Q3 2025, up from $0.9 million in Q3 2024, driven by increased professional fees and employee stock compensation[11].

Financial Performance - Revenue for the third quarter of 2025 was $2.9 million, an increase of 8% compared to $2.7 million in the same period last year[7] - The company reported a net loss of $1.7 million for the third quarter, slightly up from the same period last year[11] - Revenues for Q3 2025 reached $2,915,081, an increase from $2,705,461 in Q3 2024, representing a growth of approximately 7.8%[21] - Operating Loss for Q3 2025 was $(1,736,364), compared to $(1,599,552) in Q3 2024, reflecting a decline in performance[21] - Net Loss Attributable to Common Stockholders for Q3 2025 was $(1,700,505), compared to $(1,593,805) in Q3 2024, showing a worsening of the loss[21] - Net Loss Attributable to Common Stockholders Per Share - Basic and Diluted for Q3 2025 was $(2.21), compared to $(3,732.56) in Q3 2024, showing an improvement in loss per share[21] Expenses and Costs - Total cash operating expenses increased by $0.2 million or 5% compared to the prior-year period, totaling $3.7 million[10] - Total Operating Expenses for the nine months ended September 30, 2025, were $11,721,704, up from $10,599,924 in 2024, marking an increase of approximately 10.6%[21] - Research and Development expenses increased to $161,441 in Q3 2025 from $96,650 in Q3 2024, representing a significant rise of approximately 67.0%[21] - Advertising Costs decreased to $71,427 in Q3 2025 from $114,795 in Q3 2024, reflecting a reduction of approximately 37.7%[21] Assets and Equity - Cash and investments amounted to $11.7 million as of September 30, 2025, with no long-term debt[12] - Total assets increased to $22.37 million as of September 30, 2025, compared to $14.22 million at the end of 2024[18] - Stockholders' equity rose to $17.83 million as of September 30, 2025, up from $10.39 million at the end of 2024[18] Product Development and Innovation - The Freedom Alert Mini units and the upgraded Guardian Alert 911 Plus contributed to revenue growth[8] - The company launched Medication Reminders and Activity Metrics features on the Freedom Alert Max, enhancing AI capabilities[7] - LogicMark is focused on expanding its business-to-business channels and enhancing its product offerings to support sustainable growth[4] Profitability Metrics - Gross margin remained strong at 66%, unchanged year-over-year and year-to-date[7] - Gross Profit for the nine months ended September 30, 2025, was $5,491,594, compared to $5,123,795 for the same period in 2024, indicating a year-over-year increase of about 7.2%[21] - Interest Income for the nine months ended September 30, 2025, was $317,791, compared to $134,286 in 2024, indicating a substantial increase of about 136.5%[21] Shareholder Information - The weighted average number of common shares outstanding for Q3 2025 was 768,407, compared to 427 in Q3 2024, indicating a significant increase in shares[21]

Financial Performance - Petros reported a net income of $2,250,101 for the nine months ended September 30, 2025, compared to a net loss of $5,045,350 for the same period in 2024[108]. - The loss from continuing operations for the nine months ended September 30, 2025, was $4,163,536, compared to a loss of $152,361 in 2024[108]. - The company experienced a loss on discontinued operations of $0.6 million for the nine months ended September 30, 2025, compared to a loss of $4.9 million in 2024[116]. - Loss from continuing operations for the three months ended September 30, 2025, was $922,723, compared to a loss of $919,541 in 2024[117]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $3,809,837, reflecting a net loss of $2,250,101[175]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $3,663,934, reflecting a net loss of $5,045,350[176]. Operating Expenses - Operating expenses for the nine months ended September 30, 2025, were $4,249,864, an increase of $200,475 or 5% from $4,049,389 in 2024[109][110]. - Operating expenses for the three months ended September 30, 2025, were $990,737, a decrease of $206,622 or 17% from $1,197,359 in 2024[118][119]. Revenue and Asset Management - The company discontinued sales of Stendra® as of March 2025, impacting its revenue stream significantly[91][94]. - The company reported a gain of $7.0 million for the disposal of assets and settlement with Vivus for the nine months ended September 30, 2025, compared to $0 million in 2024[115]. - For the nine months ended September 30, 2025, the company recorded a gain of $10.3 million from the change in fair value of the warrant liability, compared to $0.0 million in the same period of 2024[113]. Financing and Capital Structure - The company is exploring various financing strategies to obtain additional liquidity, including secured or unsecured debt, convertible debt, and equity offerings[132]. - The company plans to finance near-term operations by increasing cash flows from operations and exploring additional ways to raise capital[132]. - The company has raised approximately $15 million from a private placement of Series A Preferred Stock in July 2023, which is convertible into shares of Common Stock[134]. - The Company entered into an Amendment Agreement to defer unpaid Series A Preferred Stock payments to July 15, 2025, and extend the maturity date[142]. - The Series A Preferred Stock accrues dividends at 8% per annum, increasing to 15% per annum upon a Triggering Event[146][147]. - The Company issued 558,000 units in a public offering at $6.00 per unit, raising approximately $9.6 million in gross proceeds[159]. - Net cash provided by financing activities was $8,161,458 for the nine months ended September 30, 2025, consisting of proceeds from the Public Offering[177]. Stock and Warrant Information - The exercise price of the Series A Warrants was adjusted to $0.36625 per 0.25 share following a Reverse Stock Split[160]. - The Company filed a registration statement to register for resale 200% of the Conversion Shares and Warrant Shares, effective September 18, 2023[158]. - The Series A Preferred Stock conversion price was adjusted to $0.1269 per share due to anti-dilution provisions[157]. - The Company issued 13,949 shares of Common Stock as equity awards, representing over 5% of the outstanding shares prior to the Purchase Agreement[148]. - The holders of Series A Preferred Stock are entitled to redeem their shares at a premium during a Triggering Event[146]. - The Warrant Stockholder Approval was obtained on April 10, 2025, allowing for adjustments to the exercise price and number of shares[165]. - The aggregate gross proceeds from the Public Offering were approximately $9.6 million before deducting estimated offering expenses[171]. - The Company incurred transaction costs attributable to the Series B Warrants of approximately $10.4 million, which were expensed immediately upon issuance[173]. - The fair value of the Warrants after anti-dilution adjustments was estimated at approximately $35.9 million[169]. - The exercise price of the Warrants was adjusted to $6.00 per share, and the number of shares issuable upon exercise was adjusted to 2,700,000 shares[168]. Company Structure and Compliance - As of June 16, 2025, the company assigned all assets of its subsidiaries to a third-party fiduciary, marking a significant restructuring[97]. - The company faced delisting from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements[98][102]. - The company is currently trading on the OTC Markets under the symbol "PTPI" following its delisting from Nasdaq on May 22, 2025[104][105]. - The Company has not entered into any off-balance sheet financial guarantees or derivative contracts[178]. - The Company is subject to certain covenants regarding indebtedness and asset transfers[150].

Exhibit 99.1 Financial Results for September 30, 2025 Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights – Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – Cupertino, Calif., November 13, ...